Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).
1 finding from 1 review
Change in capacity for activities of daily living · people with severe Alzheimer's disease
1 finding from 1 review
Secondary outcome: acceptability of treatment · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Change in capacity for activities of daily living · people with Alzheimer's disease
1 finding from 1 review
Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).
1 finding from 1 review
Behavioural symptoms (change from baseline at 26 weeks measured using the NPI) · people with Alzheimer's disease
1 finding from 1 review
Acceptability · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life of participants (change from baseline at 26 weeks) · people with Alzheimer's disease
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (high certainty).
1 finding from 1 review
Functional outcomes · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Cognitive function · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg showed no clear difference in clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (moderate certainty).
1 finding from 1 review
Functional outcomes · vascular dementia and other vascular cognitive impairments
1 finding from 1 review
Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments
Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).
1 finding from 1 review